GNE-8324 is primarily investigated for its potential therapeutic applications, particularly in the field of oncology. It is being studied as a selective inhibitor targeting specific kinases involved in cancer cell proliferation and survival. Early research suggests it may be effective in disrupting signaling pathways that promote tumor growth, making it a promising candidate for targeted cancer therapies. Additionally, its application extends to preclinical studies aimed at understanding its efficacy and safety profile in various cancer models. Researchers are also exploring its potential in combination therapies to enhance treatment outcomes and overcome drug resistance in certain malignancies.